195 related articles for article (PubMed ID: 32967778)
21. Successful management of eosinophilic chronic rhinosinusitis complicated by severe asthma using dupilumab, following negative initial results with benralizumab.
Suzaki I; Tanaka A; Hirano K; Arai S; Kobayashi H
Allergol Int; 2021 Jan; 70(1):150-152. PubMed ID: 32507512
[No Abstract] [Full Text] [Related]
22. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
[TBL] [Abstract][Full Text] [Related]
23. Comparison of clinical characteristics of the nasal manifestations of eosinophilic granulomatosis with polyangiitis (EGPA) and eosinophilic chronic rhinosinusitis (ECRS).
Suzuki M; Nakazono A; Morita S; Fukuda A; Honma A; Suzuki T; Kimura S; Nakamaru Y; Homma A
Allergol Int; 2021 Jan; 70(1):143-144. PubMed ID: 32636058
[No Abstract] [Full Text] [Related]
24. A Pediatric Case of Relapsing Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab.
Nara M; Saito M; Abe F; Komatsuda A; Wakui H; Takahashi N
Intern Med; 2019 Dec; 58(24):3583-3587. PubMed ID: 31391393
[TBL] [Abstract][Full Text] [Related]
25. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.
Nagase H; Ueki S; Fujieda S
Allergol Int; 2020 Apr; 69(2):178-186. PubMed ID: 32139163
[TBL] [Abstract][Full Text] [Related]
26. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Sun R; Wei LJ
N Engl J Med; 2024 May; 390(20):1939. PubMed ID: 38810203
[No Abstract] [Full Text] [Related]
27. Early benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis.
Colantuono S; Pellicano C; Leodori G; Cilia F; Francone M; Visentini M
Allergol Int; 2020 Jul; 69(3):483-484. PubMed ID: 32224025
[No Abstract] [Full Text] [Related]
28. Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders.
Olivieri B; Tinazzi E; Caminati M; Lunardi C
Immunol Allergy Clin North Am; 2020 Nov; 40(4):649-665. PubMed ID: 33012326
[TBL] [Abstract][Full Text] [Related]
29. Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review.
Raffray L; Guillevin L
Drugs; 2018 Jun; 78(8):809-821. PubMed ID: 29766394
[TBL] [Abstract][Full Text] [Related]
30. Successful early introduction of mepolizumab for peripheral neuropathy with a peripheral circulatory disorder in a patient with myeloperoxidase anti-neutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis.
Nishihara M; Hamaguchi M; Ikumi N; Nishiwaki A; Sugiyama K; Nagasawa Y; Tsuzuki H; Yoshizawa S; Tanikawa Y; Asatani S; Kobayashi H; Takei M; Kitamura N
Mod Rheumatol Case Rep; 2021 Jul; 5(2):354-359. PubMed ID: 33970058
[TBL] [Abstract][Full Text] [Related]
31. Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media.
Iino Y; Takahashi E; Ida S; Kikuchi S
Auris Nasus Larynx; 2019 Apr; 46(2):196-203. PubMed ID: 30122651
[TBL] [Abstract][Full Text] [Related]
32. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study.
Detoraki A; Di Capua L; Varricchi G; Genovese A; Marone G; Spadaro G
J Asthma; 2016; 53(2):201-6. PubMed ID: 26377630
[TBL] [Abstract][Full Text] [Related]
33. Eosinophilic granulomatosis with polyangiitis demonstrating IgE-immune complexes and the possible involvement of IgE autoantibodies.
Ota Y; Fujiwara M; Hirabayashi Y; Kumasaka T; Takemura T; Ota R; Suzuki M; Inokuma S
Intern Med; 2015; 54(20):2687-91. PubMed ID: 26466712
[TBL] [Abstract][Full Text] [Related]
34. Eosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the disease.
Berti A; Boukhlal S; Groh M; Cornec D
Expert Rev Clin Immunol; 2020 Jan; 16(1):51-61. PubMed ID: 31762336
[No Abstract] [Full Text] [Related]
35. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs.
Varricchi G; Bagnasco D; Borriello F; Heffler E; Canonica GW
Curr Opin Allergy Clin Immunol; 2016 Apr; 16(2):186-200. PubMed ID: 26859368
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological profile of mepolizumab.
Pauk N
Vnitr Lek; 2023; 69(5):322-328. PubMed ID: 37827831
[TBL] [Abstract][Full Text] [Related]
37. Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: What is the right dose?
Akdime F; Puéchal X; Roche N
J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2942-2943. PubMed ID: 34246444
[No Abstract] [Full Text] [Related]
38. Forced oscillation technique as method to document and monitor the efficacy of mepolizumab in treating severe eosinophilic asthma.
Antonicelli L; Tontini C; Marchionni A; Lucchetti B; Garritani MS; Bilò MB
Allergy; 2020 Feb; 75(2):433-436. PubMed ID: 31166020
[No Abstract] [Full Text] [Related]
39. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
Gupta A; Ikeda M; Geng B; Azmi J; Price RG; Bradford ES; Yancey SW; Steinfeld J
J Allergy Clin Immunol; 2019 Nov; 144(5):1336-1342.e7. PubMed ID: 31425781
[TBL] [Abstract][Full Text] [Related]
40. Low-dose mepolizumab is effective as an add-on therapy for treating long-lasting peripheral neuropathy in patients with eosinophilic granulomatosis with polyangiitis.
Nakamura Y; Fukutomi Y; Sekiya K; Kajiwara K; Kawasaki Y; Fujita N; Nagayama K; Iwata M; Iwamoto K; Yano K; Hamada Y; Watai K; Ryu K; Hayashi H; Kamide Y; Taniguchi M
Mod Rheumatol; 2022 Feb; 32(2):387-395. PubMed ID: 34910206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
